Bupa Aged Care has been ordered to pay a $6 million penalty for charging customers of its aged care facilities for services it never provided, including enhancements intended to improve the quality of life for its most vulnerable residents, such as those suffering from dementia and blindness.
A judge has found that the law firm behind a plethora of pelvic mesh lawsuits filed in multiple courts should be personally hit with costs for its “keystone cop-like conduct” in handling the proceedings, but has given the firm a week to convince him otherwise.
The top judge of the Federal Court plans to clear the schedules of three judges at the start of next year so they can hear and decide Johnson & Johnson’s challenge of a class action ruling that found its pelvic mesh devices were defective and awarded the lead applicants $2.6 million in damages.
A court has dismissed a claim by the Australian Government for $325 million against pharmaceutical companies Sanofi and Bristol-Myers Squibb allegedly owed for excess subsidies it paid for blood-thinner Plavix as a result of an interlocutory injunction blocking a generic version of the blockbuster drug.
Celebrity chef Pete Evans has been fined $25,200 by the Therapeutic Goods Administration for claiming an expensive light machine dubbed the Biocharger could help protect people from the coronavirus.
Two gynaecologists have lost their bid to dismiss a negligence lawsuit brought by a patient implanted with a Johnson & Johnson pelvic mesh device found by a judge overseeing a related class action to have been defective.
The makers or popular opioid drugs like OxyContin and Fentanyl may face a class action in Australia by consumers who allege they suffered financial loss from the addictive drugs.
The Australian Competition and Consumer Commission has taken swift action to allow medical technology companies to coordinate on supplying ventilators, protective gear and other equipment in high demand due to the coronavirus.
Generic drug maker Juno Pharmaceuticals has agreed to stopped planned sales of its cheap version of Millennium Pharmaceuticals anti-cancer medication Velcade in Australia as part of a settlement of its lawsuit alleging two patents covering the drug were invalid.
AFT Pharmaceuticals has lost its challenge to a ruling that ads claiming its painkiller Maxigesic is more effective than Nuremol were misleading and deceptive, with the Full Federal Court saying the primary judge did not err in finding the ads lacked an adequate scientific basis.